Blood Cancer Journal (Jan 2023)
Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial
- Yingling Zu,
- Ruirui Gui,
- Zhen Li,
- Juan Wang,
- Yanli Zhang,
- Fengkuan Yu,
- Huifang Zhao,
- Xinrong Zhan,
- Zhongliang Wang,
- Pengtao Xing,
- Xianjing Wang,
- Huili Wang,
- Yongping Song,
- Jian Zhou
Affiliations
- Yingling Zu
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
- Ruirui Gui
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
- Zhen Li
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
- Juan Wang
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
- Yanli Zhang
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
- Fengkuan Yu
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
- Huifang Zhao
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
- Xinrong Zhan
- Department of Hematology, Central Hospital of Xinxiang
- Zhongliang Wang
- Department of Hematology, Central Hospital of Xinxiang
- Pengtao Xing
- Department of Hematology, Central Hospital of Xinxiang
- Xianjing Wang
- Department of Hematology, The Third People’s Hospital of Zhengzhou
- Huili Wang
- Department of Hematology, The Third People’s Hospital of Zhengzhou
- Yongping Song
- Department of Hematology, the First Affiliated Hospital of Zhengzhou University
- Jian Zhou
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
- DOI
- https://doi.org/10.1038/s41408-022-00771-w
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 4
Abstract
No abstracts available.
